Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
AbbVie is one of the largest global biopharmaceutical companies, with major businesses in immunology, oncology, neuroscience, aesthetics, and eye care. Its latest results show that 2025 set a new revenue peak for the company even after years of Humira erosion.
Quick Answer: AbbVie delivered $61.2 billion in worldwide net revenues in 2025 and reported full-year diluted EPS of $2.36 on a GAAP basis. For 2026, AbbVie expects strong continued growth led by immunology, including projected global immunology sales of about $34.5 billion.
Key AbbVie Metrics
| Metric | Figure | Year |
|---|---|---|
| Worldwide net revenues | $61.2 billion | 2025 |
| Q4 net revenues | $16.618 billion | Q4 2025 |
| GAAP diluted EPS | $2.36 | 2025 |
| Employees | About 55,000 | 2024 latest annual-report base |
| 2026 global immunology sales target | $34.5 billion | 2026 guidance context |
About AbbVie
AbbVie has evolved from a Humira-dominated company into a much more diversified drugmaker with strong growth from Skyrizi, Rinvoq, neuroscience, and aesthetics. That diversification is a central part of its 2025 and 2026 story.
AbbVie Revenue Statistics
- 2025: $61.2 billion
- 2024: $56.3 billion
- 2023: $54.318 billion
- 2022: $58.054 billion
- 2021: $56.197 billion
- 2020: $45.804 billion
- 2019: $33.266 billion
- 2018: $32.753 billion
- 2017: $28.216 billion
- 2016: $25.638 billion
- 2015: $22.859 billion
- 2014: $19.960 billion
- 2013: $18.790 billion
AbbVie Net Earnings Statistics
- 2025: see GAAP diluted EPS of $2.36; Q4 net income was $1.82 billion
- 2024: about $4.3 billion
- 2023: $4.873 billion
- 2022: $11.845 billion
- 2021: $11.549 billion
- 2020: $4.622 billion
- 2019: $7.882 billion
- 2018: $5.687 billion
- 2017: $5.309 billion
- 2016: $5.953 billion
- 2015: $5.144 billion
- 2014: $1.774 billion
2025 Update
AbbVie reported a record $61.2 billion in total net revenues for 2025, driven by strong growth from Skyrizi and Rinvoq, along with continued contributions from neuroscience and aesthetics.
2026 Update
AbbVie’s 2026 outlook remains centered on immunology expansion. The company expects approximately $34.5 billion in global immunology sales, including around $21.5 billion from Skyrizi and $10 billion from Rinvoq.
Workforce and Global Footprint
AbbVie’s public reporting shows a workforce that is materially larger than the older 47,000-employee figure often repeated online. The company’s ESG materials also point to broad international operations and community involvement.
FAQ
What was AbbVie revenue in 2025?
AbbVie reported $61.2 billion in worldwide net revenues in 2025.
What were AbbVie’s fourth-quarter 2025 revenues?
AbbVie reported $16.618 billion in worldwide net revenues in the fourth quarter of 2025.
How many employees does AbbVie have?
The latest annual-report base showed about 55,000 employees.
What is AbbVie expecting in 2026?
AbbVie expects strong continued immunology growth in 2026, including projected global immunology sales of about $34.5 billion.
Sources and References
